Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDS‐Flow</scp> Cytometry Working Group
Arjan A. van de Loosdrecht, Wolfgang Kern, Anna Porwit, Peter Valent, Shahram Kordasti, Eline M.P. Cremers, Canan Alhan, Carolien Duetz, Alan Dunlop, Willemijn Hobo, Frank Preijers, Orianne Wagner‐Ballon, Nicolas Chapuis, Michaëla Fontenay, Peter Bettelheim, Lisa Eidenschink‐Brodersen, Patricia Font, Ulrika Johansson, Michael R. Loken, Jeroen G. te Marvelde, Sergio Matarraz, Kíyoyuki Ogata, Uta Oelschlaegel, Alberto Órfão, Katherina Psarra, Dolores Subirá, Denise A. Wells, Marie C. Béné, Matteo Giovanni Della Porta, Kate Burbury, Frauke Bellos, Vincent H. J. van der Velden, Theresia M. Westers, Leonie Saft, Robin Ireland
Abstract
This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.